Alaunos Therapeutics, Inc. (TCRT) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Oct 13, 2026
Alaunos Therapeutics, Inc. (TCRT)
A forensic read on Alaunos Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-1020.5
Distress distance
Clean
Earnings quality
3
Forensic signals
-194.0%
ROE
-50.0%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Alaunos Therapeutics, Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -1020.5, placing it in the Distress zone. 3 forensic signals were flagged in its latest SEC filings, led by share-count dilution.
What the filings flag
+10.4%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +22% over the last 2 years to FY2025 (+10.4%/yr). The count is growing — 1.6M shares in FY2023, 1.9M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~10.4% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~18%.
15920% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 15920% of revenue in FY2025 — about $0.41 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 10.4% a year across FY2023–FY2025 and that rate is not falling, so total profit has to grow by that much annually before any of it reaches a share. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
-$38.0M
FY2023–FY2025
Cash burn vs. reported loss.Over FY2023–FY2025, the company reported a cumulative net loss of $13.5M against operating cash flow of -$38.0M. Cash burn ran heavier than the reported loss — something outside net income (working capital, a cash item not in the P&L) is consuming cash faster than the loss alone implies.
Key fundamentals
Latest Revenue$5,000.00
Revenue Growth YoY-50.0%
Revenue CAGR (2yr)+0.0%
Net Margin-83520.0%
Free Cash Flow-$3.0M
Return on Equity-194.0%
Debt / Equity0.00x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Alaunos Therapeutics, Inc.'s actual 10-K/10-Q/8-K filings?